Skip to Content

Join the 'Exemestane' group to help and get support from people like you.

Exemestane News

Certain Breast Cancer Drugs Tied to Blood Vessel Damage

Posted 1 day 11 hours ago by Drugs.com

FRIDAY, Dec. 9, 2016 – Women on breast cancer drugs called aromatase inhibitors may show signs of early blood vessel damage that could lead to heart disease, a small study suggests. Researchers found that compared with healthy women their age, women on aromatase inhibitors were more likely to show signs of "endothelial dysfunction." That refers to problems in how the blood vessel lining responds to blood flow. The findings are based on just 36 women who were prescribed the drugs. And experts stressed it's too early to know what to make of the results. Still, the study adds to evidence linking aromatase inhibitors to elevated risks of high blood pressure, high cholesterol and possibly full-blown heart disease. Aromatase inhibitors include the drugs Aromasin (exemestane), Arimidex (anastrozole) and Femara (letrozole). These drugs work by lowering a woman's estrogen levels, and are often ... Read more

Related support groups: Heart Disease, Breast Cancer, Arimidex, Femara, Breast Cancer, Metastatic, Anastrozole, Letrozole, Aromasin, Exemestane, Breast Cancer, Prevention, Breast Cancer - Palliative, Osteolytic Bone Metastases of Breast Cancer, Teslac, Testolactone, Infectious Heart Disease

New Drug Combo Shows Promise Curbing Tough-to-Treat Breast Cancer

Posted 2 days 10 hours ago by Drugs.com

THURSDAY, Dec. 8, 2016 – In women with a certain form of tough-to-treat breast cancer, treatment with a combination of two drugs appeared to keep the cancer at bay longer – from about five months to 10, a new study says. The cancer is known as "advanced hormone receptor positive, HER 2 negative" breast cancer. Women with these tumors are often given drugs called aromatase inhibitors, which work by reducing estrogen in the body and slowing the growth of the cancer. However, patients commonly develop resistance to aromatase inhibitor drugs, and they stop working. This is also known as endocrine therapy resistance. The new research may offer these patients some hope, researchers said. "Our study has shown that combining a newer medicine called everolimus [Afinitor] with a more established medicine, fulvestrant [Faslodex], has demonstrated benefit in aromatase inhibitor resistant breast ... Read more

Related support groups: Breast Cancer, Estradiol, Premarin, Ethinyl Estradiol, Estrace, Arimidex, Femara, Vagifem, Estrace Vaginal Cream, Vivelle, Breast Cancer, Metastatic, Anastrozole, Climara, Letrozole, Estring, Premarin Vaginal, Vivelle-Dot, Aromasin, Afinitor, Estradiol Patch

Breast Cancer Cells May Change When They Spread to Brain: Study

Posted 3 days ago by Drugs.com

WEDNESDAY, Dec. 7, 2016 – When breast cancer spreads to the brain, important molecular changes may occur in the cancer, a small study found. The discovery of these changes could lead to improved diagnosis and treatment, the researchers said. About 20 percent of breast cancers are a type known as HER2-positive, which typically respond to targeted therapies. However, HER2-negative breast cancer that has spread to the brain doesn't respond to the same therapies. In this study, researchers analyzed tumors from 20 patients in the United States and Ireland. They found that primary breast cancer identified as HER2-negative switched to HER2-positive when it spread to the brain. The findings show that treatments should target not only the original breast cancer, but also brain tumors, said study author Adrian Lee, director of the Institute for Precision Medicine, part of the University of ... Read more

Related support groups: Breast Cancer, Estradiol, Premarin, Ethinyl Estradiol, Estrace, Arimidex, Femara, Vagifem, Estrace Vaginal Cream, Vivelle, Breast Cancer, Metastatic, Anastrozole, Climara, Letrozole, Estring, Premarin Vaginal, Vivelle-Dot, Aromasin, Estradiol Patch, Herceptin

Taking Breast Cancer Prevention Drug Beyond 5 Years May Not Raise Survival

Posted 4 days ago by Drugs.com

WEDNESDAY, Dec. 7, 2016 – Many breast cancer survivors take anti-estrogen drugs for at least five years to help lessen their risk of recurrence. Now, new research suggests that taking such a drug for an even longer period might not confer any added benefit – at least in terms of survival. The study of thousands of older breast cancer survivors found that taking the aromatase inhibitor drug letrozole (Femara) for more than the recommended five years did not help them live longer. However, other benefits were noted, so the decision to extend use of drugs like these is one best made on a case-by-case basis, cancer specialists said. One oncologist who reviewed the new findings said the study has been "eagerly awaited," since many breast cancer survivors are counseled to take an aromatase inhibitor. "For now, this trial reinforces the need to listen to our patients and weigh out the risk ... Read more

Related support groups: Breast Cancer, Arimidex, Femara, Breast Cancer, Metastatic, Anastrozole, Letrozole, Aromasin, Breast Cancer - Adjuvant, Exemestane, Breast Cancer, Prevention, Breast Cancer - Palliative, Osteolytic Bone Metastases of Breast Cancer, Breast Cancer - Male, Teslac, Testolactone

Intense Chemo Offers Little Benefit for Early Breast Cancer: Study

Posted 9 Nov 2016 by Drugs.com

WEDNESDAY, Nov. 9, 2016 – A more intense type of chemotherapy offers little benefit over standard chemotherapy for women with high-risk early breast cancer, European researchers report. Known as tailored dose-dense chemotherapy, the treatments are given over a shorter period of time without increasing the overall dose. It has been suggested as a way to improve the effectiveness of the treatment for early breast cancer. However, the European study did not find a difference in recurrence-free survival or overall survival after five years of follow-up. The investigators did find that the dose-dense group had better event-free survival, defined as the time to any breast cancer relapse, cancer in the opposite breast, other malignant growths or death from any cause. Despite the results, a U.S. breast cancer expert said there is still a role for the approach in certain women. Researchers from ... Read more

Related support groups: Provera, Depo-Provera, Breast Cancer, Lupron, Tamoxifen, Medroxyprogesterone, Arimidex, Femara, Lupron Depot, Breast Cancer, Metastatic, Anastrozole, Evista, Zoladex, Megestrol, Letrozole, Megace, Aromasin, Herceptin, Breast Cancer - Adjuvant, Casodex

More Evidence Tamoxifen, Other Meds Help Limit Breast Cancer's Spread

Posted 6 Oct 2016 by Drugs.com

THURSDAY, Oct. 6, 2016 – Treatment with tamoxifen or another class of drugs called aromatase inhibitors does cut breast cancer patients' risk of developing cancer in their other breast, a new study finds. Some breast cancers rely on estrogen to help them grow, and drugs like tamoxifen or the aromatase inhibitors (which include anastrozole) have long been prescribed to certain breast cancer survivors. Tamoxifen blocks estrogen receptors in the breast cells to hamper cancer growth. Anastrozole stops estrogen production in fat tissue, which makes small amounts of the hormone. According to background information in the new study, about 5 percent of breast cancer patients develop cancer in their other breast (contralateral breast cancer) within 10 years after their initial breast cancer diagnosis. Prior clinical trials had concluded that tamoxifen and aromatase inhibitors reduce this risk, ... Read more

Related support groups: Breast Cancer, Tamoxifen, Arimidex, Femara, Breast Cancer, Metastatic, Anastrozole, Letrozole, Aromasin, Breast Cancer - Adjuvant, Exemestane, Breast Cancer, Prevention, Breast Cancer - Palliative, Tamoxifen Hexal, Tamosin, Nolvadex, Testolactone, Soltamox, Tamone, Emblon, Tamoxen

Smoking May Hinder Common Breast Cancer Treatment

Posted 24 Jun 2016 by Drugs.com

FRIDAY, June 24, 2016 – Smoking may blunt the effectiveness of a certain kind of breast cancer treatment, new research suggests. Among breast cancer patients taking a class of drugs called aromatase inhibitors, smokers had a three times greater risk of their cancer returning than nonsmokers, the investigators found. However, the study could not prove a cause-and-effect link. Smoking had little or no effect on the benefit of other drugs, such as chemotherapy or tamoxifen, or radiation treatment, the study authors added. "These findings need confirmation. If confirmed, smoking status should be taken into consideration when selecting the type of [breast cancer] therapy," said lead researcher Helena Jernstrom. She is an associate professor of experimental oncology at Lund University Cancer Center in Sweden. Common aromatase inhibitors include Arimidex (anastrozole), Aromasin (exemestane) ... Read more

Related support groups: Smoking, Breast Cancer, Smoking Cessation, Arimidex, Femara, Breast Cancer, Metastatic, Anastrozole, Letrozole, Aromasin, Breast Cancer - Adjuvant, Exemestane, Breast Cancer, Prevention, Breast Cancer - Palliative, Osteolytic Bone Metastases of Breast Cancer, Teslac, Testolactone

Longer Use of Certain Drugs Cuts Recurrence for Breast Cancer Survivors

Posted 6 Jun 2016 by Drugs.com

MONDAY, June 6, 2016 – Many survivors of breast cancers that are sensitive to estrogen are advised to take hormone-suppressing drugs such as tamoxifen for five years, to cut their odds for a recurrence. Tamoxifen can have onerous side effects, however. Now, new research finds that taking an alternative, and less troublesome, class of medications for a full decade can reduce the risk for recurrence even more – without affecting a woman's quality of life. The newer class of hormone-suppressing drugs are called aromatase inhibitors, and include drugs such as letrozole (Femara), anastrozole (Arimidex) and exemestane (Aromasin). "Aromatase inhibitors do not have all the side effects of tamoxifen and overall are much better tolerated than tamoxifen," explained one breast cancer expert, Dr. Stephanie Bernik. She believes the new study supports the benefit of aromatase inhibitors, and "women ... Read more

Related support groups: Breast Cancer, Tamoxifen, Arimidex, Femara, Breast Cancer, Metastatic, Anastrozole, Letrozole, Aromasin, Breast Cancer - Adjuvant, Exemestane, Breast Cancer, Prevention, Breast Cancer - Palliative, Osteolytic Bone Metastases of Breast Cancer, Tamoxifen Hexal, Tamosin, Nolvadex, Soltamox, Tamone, Emblon, Tamoxen

U.S. Pays Highest Prices for Cancer Meds: Study

Posted 6 Jun 2016 by Drugs.com

MONDAY, June 6, 2016 – The United States pays the highest prices in the world for generic and brand-name cancer drugs, a new study has found. However, as the world's wealthiest nation, the United States is better able to pay for those pricey drugs than poorer countries with somewhat lower medication prices, added study lead author Dr. Daniel Goldstein. People in China and India are much less able to afford cancer drugs than Americans, he said, even though U.S. monthly drug prices are about three to six times higher in the United States. That doesn't mean America came out on top in overall drug affordability, however. Developed nations such as Australia, England and Israel had the "best deal" in the world on cancer drugs, thanks to government programs that regulate drug pricing, the study found. "America is the wealthiest nation, but its drug prices are significantly higher – so much ... Read more

Related support groups: Cancer, Provera, Depo-Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Tamoxifen, Medroxyprogesterone, Arimidex, Tretinoin, Fluorouracil, Lupron Depot, Femara, Gleevec, Lung Cancer, Colorectal Cancer, Rituxan, Isotretinoin, Claravis

Breast Cancer Meds Won't Raise Chances of Heart Attack, Stroke, Study Suggests

Posted 21 Apr 2016 by Drugs.com

THURSDAY, April 21, 2016 – Treatment with estrogen-lowering drugs called aromatase inhibitors doesn't raise the risk of heart attacks and strokes among breast cancer survivors, a new study suggests. However, the researchers did find that women who took the drugs had a slightly higher risk of less serious heart problems, such as an abnormal heart beat or swelling and irritation of the membrane surrounding the heart. "Our study is a comprehensive assessment of the impact aromatase inhibitors have on cardiovascular risk and provides reassurance that the hormone therapy to reduce breast cancer recurrence does not increase risk of the most fatal cardiovascular events," said study author Reina Haque. She is a research scientist at Kaiser Permanente's Southern California Department of Research and Evaluation. "A particular strength of our study is that we accounted for women's other potential ... Read more

Related support groups: Heart Disease, Breast Cancer, Tamoxifen, Arimidex, Femara, Breast Cancer, Metastatic, Anastrozole, Letrozole, Aromasin, Breast Cancer - Adjuvant, Exemestane, Breast Cancer, Prevention, Breast Cancer - Palliative, Breast Cancer - Male, Tamoxifen Hexal, Tamosin, Nolvadex, Soltamox, Testolactone, Tamone

Early Chemo Less Likely to Help Black Breast Cancer Patients: Study

Posted 12 Dec 2015 by Drugs.com

FRIDAY, Dec. 11, 2015 – Early chemotherapy is less likely to benefit black women with breast cancer than those in other racial and ethnic groups, a new study finds. Advanced breast cancer is more common among black, Hispanic and Asian women than it is in white women. As a result, black women often receive chemotherapy before surgery in an effort to improve their outcomes, the Yale University Cancer Center researchers said. But their study of 27,300 women with stage 1 to 3 breast cancer showed that early (neoadjuvant) chemotherapy was less effective in black patients than in other women. "Even when we controlled for the fact that minority women often present with more advanced-stage, higher-grade tumors, and more aggressive types of breast cancer overall, our team was surprised to find that black women did not respond as well to neoadjuvant chemotherapy compared to other racial groups," ... Read more

Related support groups: Provera, Depo-Provera, Breast Cancer, Lupron, Tamoxifen, Medroxyprogesterone, Arimidex, Femara, Lupron Depot, Breast Cancer, Metastatic, Anastrozole, Zoladex, Evista, Megestrol, Letrozole, Megace, Aromasin, Herceptin, Casodex, Breast Cancer - Adjuvant

Two Drugs Equal in Preventing Early Breast Cancer's Return: Study

Posted 11 Dec 2015 by Drugs.com

FRIDAY, Dec. 11, 2015 – Postmenopausal women who have an early, noninvasive form of breast cancer had similar recurrence rates of disease whether they took the drug tamoxifen or the aromatase inhibitor anastrozole after surgery, new research shows. However, the side effects of the two medications differed greatly, said study author Jack Cuzick, director of the Wolfson Institute of Preventive Medicine at Queen Mary University of London, England. His team looked at nearly 3,000 women, all past menopause, who had hormone-receptor positive ductal carcinoma in situ (DCIS) breast cancer and underwent surgery to excise it. With DCIS, the cells that line the milk ducts have changed but not spread into the surrounding breast tissue. Half the women were randomly assigned to take 1 milligram (mg) a day of anastrozole (Arimidex), while the other half took 20 mg a day of tamoxifen (Nolvadex). Each ... Read more

Related support groups: Provera, Depo-Provera, Breast Cancer, Lupron, Tamoxifen, Medroxyprogesterone, Arimidex, Femara, Lupron Depot, Breast Cancer, Metastatic, Anastrozole, Zoladex, Evista, Megestrol, Letrozole, Megace, Aromasin, Herceptin, Casodex, Breast Cancer - Adjuvant

Timing May Be Key to Success of Surgery, Chemo for Early Breast Cancer

Posted 10 Dec 2015 by Drugs.com

THURSDAY, Dec. 10, 2015 – The sooner early stage breast cancer patients have surgery following their diagnosis, and chemotherapy after their surgery, the better their chances of survival, two new studies find. In one study, researchers at Fox Chase Cancer Center in Philadelphia analyzed data from more than 94,500 American women aged 66 and older. All were diagnosed with breast cancer between 1992 and 2009. The team, led by Dr. Richard Bleicher, found a 9 percent increased risk of death from all causes for each 30-day delay in the time from diagnosis to surgery. The link between time to surgery and risk of death from all causes was only statistically significant for patients with earlier stages of cancer, the researchers noted. In the study, delays seemed to affect prognosis for patients with stage 1 and stage 2 cancers, but not for those with stage 3 cancers. The findings were similar ... Read more

Related support groups: Surgery, Provera, Depo-Provera, Breast Cancer, Lupron, Tamoxifen, Medroxyprogesterone, Arimidex, Femara, Lupron Depot, Breast Cancer, Metastatic, Anastrozole, Zoladex, Evista, Megestrol, Letrozole, Megace, Aromasin, Herceptin, Casodex

Depression May Be Tied to Lower Breast Cancer Survival

Posted 10 Dec 2015 by Drugs.com

THURSDAY, Dec. 10, 2015 – Breast cancer patients with depression may have a much higher risk of death than those without the mental illness, a new study suggests. "Low mood and depression are understandable reactions to a breast cancer diagnosis. Clinicians generally know to look out for this, but these findings emphasize the need to ask patients with cancer about their mood and for women to know it's OK to ask for help," Elizabeth Davies, of the division of health and social care research and cancer studies at King's College London, said in a school news release. "It is important women feel they can talk about these feelings and do not feel guilty about difficulty coping or depression, which can be a natural response to cancer diagnosis," she added. Although this study found a link between depression and breast cancer survival, it's important to note that the research can't prove ... Read more

Related support groups: Depression, Lexapro, Zoloft, Cymbalta, Effexor, Prozac, Provera, Major Depressive Disorder, Celexa, Depo-Provera, Citalopram, Paxil, Sertraline, Pristiq, Amitriptyline, Fluoxetine, Venlafaxine, Effexor XR, Breast Cancer, Mirtazapine

Lumpectomy Plus Radiation May Beat Mastectomy for Early Breast Cancer

Posted 10 Dec 2015 by Drugs.com

THURSDAY, Dec. 10, 2015 – Women with early stage breast cancer may survive longer if they opt for the less-extensive surgery called lumpectomy, followed by radiation, rather than a mastectomy, a new study suggests. "I think these results offer women important information to discuss with their doctors when making a treatment decision for early stage breast cancer," said lead researcher Sabine Seisling, of the Netherlands Comprehensive Cancer Organization, in Utrecht. Mastectomy removes the entire the breast, while lumpectomy involves removing only the tumor with some surrounding tissue. Some studies have suggested that women with early stage breast cancer have a better five-year survival rate after lumpectomy. The new study, which included 37,000 Dutch women, found that the advantage may also extend to the longer term. Of nearly 22,000 patients who underwent lumpectomy plus radiation, ... Read more

Related support groups: Surgery, Cancer, Provera, Depo-Provera, Breast Cancer, Lupron, Tamoxifen, Medroxyprogesterone, Arimidex, Femara, Lupron Depot, Anastrozole, Evista, Zoladex, Megestrol, Letrozole, Megace, Aromasin, Casodex, Breast Cancer - Adjuvant

Page 1 2 3 Next

Ask a Question

Further Information

Related Condition Support Groups

Breast Cancer

Related Drug Support Groups

Aromasin

Exemestane Patient Information at Drugs.com